Federico Cappuzzo - Researcher Profile

Publications

4 shown

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee , David C. Turner , Enriqueta Felip +20 more

2016 Annals of Oncology 157 citations

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi , Julien Mazières , David Planchard +27 more

2015 The Lancet Oncology 1406 citations

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon , Tudor‐Eliade Ciuleanu , Óscar Arrieta +23 more

2014 The Lancet 1263 citations

Frequent Co-Authors

Researcher Info

h-index: 4
Publications: 4
Citations: 6,418
Institution: Azienda Unità Sanitaria Locale Della Romagna

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6295-6767

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.